AbOliGo

Executive Summary

AbOliGo is a UK-based biotechnology company founded in 2019 that specializes in the rapid development and supply of antibody-oligonucleotide conjugates (AOCs). Its proprietary platform enables the production of these critical reagents within three days, addressing a key bottleneck in multiplexed protein analysis, spatial biology, and single-cell proteomics. By offering both a catalog of pre-designed AOCs and a custom conjugation service from microgram to milligram scale, AbOliGo empowers researchers to accelerate their workflows. The company is positioned at the intersection of the growing fields of proteomics and spatial genomics, where the demand for high-quality, reproducible AOCs is expanding rapidly. With its UK base and focus on speed and scalability, AbOliGo aims to become a preferred partner for life science researchers transitioning from traditional immunoassays to more sophisticated multiplexed detection methods. The company has not disclosed funding or stage, suggesting it may be in early revenue generation or seeking seed investment.

Upcoming Catalysts (preview)

• Q3 2026Launch of expanded AOC catalog for spatial biology targets80% success
• Q1 2027Strategic partnership with a spatial biology platform company (e.g., 10x Genomics, Akoya)40% success
• Q4 2026Series A funding round to scale manufacturing and commercialization50% success